P3 Primary Cell 4D-Nucleofector™ X Kit L
P3 Primary Cell 4D-Nucleofector™ X Kit L
Select Size
Product Overview
The P3 Primary Cell 4D-NucleofectorTM X Kit L is one of our five 4D-NucleofectorTM Kits suited for transfecting primary cells in the 100 µL NucleocuvetteTM Vessel format when working with the 4D-NucleofectorTM X Unit.
This kit has been determined to be optimal for transfecting following cell types:
- B cell (human)
- CD34+ cell (human)
- Chondrocyte (human)
- DC (human)
- DC (mouse), mature
- ES (human), H9
- ES (mouse)
- Hepatocyte (human)
- HMEC (human)
- Keratinocyte (human)
- Macrophage (human)
- Monocyte (human)
- Neuron (rat), brain Hi/Cx
- NHBE (human)
- RPE (human)
- T cell (human), stim.
- T cell (human), unstim.
- T cell (mouse), unstim.
The respective cell type-specific Optimized Protocols are available under "Instructions" or in our knowledge database. In these Optimized Protocols the best Nucleofection conditions are indicated. In addition, we share our experience and knowledge for treatment of individual cell types. The kit is available in different variants for either 12 or 24 reactions.
Request More InfoBenefits
- High transfection efficiencies in for primary cells
- Cells maintain functionality post transfection
- Conditions are transferable between 4D NucleofectorTM System, 96-well ShuttleTM System and 384-well NucleofectorTM System
Applications
- Transfection of cell numbers in the range of 2 × 105 to 2 × 107 cells
- Low throughput applications
Storage and Content
2 x 0.675 mL P3 Primary Cell NucleofectorTM Solution
2 x 0.15 mL Supplement 1
50 µg pmaxGFPTM Vector (1 μg/μl in 10 mM Tris pH 8.0)
12 x 100 µL NucleocuvetteTM Vessels
12 x Single use pipettes
SDS, CoA, and Instructions
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
Educational Material
Brochures, White Papers etc.
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cells
A strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells. -
Transfection of Human Induced Pluripotent Stem Cells using Nucleofector® Technology
Technical Reference Guide providing tips for transfecting iPSCs using the Nucleofector® Technology
